Visit our USA website
Re:Cognition Health is delighted to announce that we have been shortlisted for the HealthInvestor 2026 Award – Diagnostics Provider of the Year. This nomination reflects our ongoing commitment to early and accurate diagnosis, pioneering treatments and improving outcomes for people affected by neurological conditions.
For over a decade, Re:Cognition Health has been at the forefront of innovation in brain health. We have played a pivotal role in the development of the first disease-modifying treatments for Alzheimer’s disease, including lecanemab (Leqembi) and donanemab (Kisunla). By targeting the underlying amyloid pathology of Alzheimer’s rather than just relieving symptoms, these therapies mark a significant paradigm shift in dementia care. Our Founder and CEO, Dr Emer MacSweeney, served as UK Principal Investigator for the clinical trials that supported global approval of these medicines, enabling thousands of participants to contribute to this landmark research.
Today, Re:Cognition Health is one of Europe’s leading providers offering these treatments privately, with clinics in London, Bristol, Birmingham and Winchester, as well as centers in the US. Patients from over 20 countries now travel to our UK clinics to access the services and esteemed medical care, highlighting our international reputation for excellence.
Our commitment to early detection and personalised care is further embodied in our Cognitive Health and Memory Assessment, launched in 2025 in collaboration with scan.com. Combining structured cognitive testing, p-Tau217 blood biomarkers, high-resolution MRI and specialist consultations, this integrated service empowers patients with actionable insights into their cognitive health.
Beyond clinical services, Re:Cognition Health actively advocates for brain health awareness. Dr MacSweeney’s TEDx talks, media contributions, and thought leadership have reached millions, reinforcing the importance of early intervention and prevention.
Innovation also extends to our operations. Our AI-powered patient enrolment system ensures seamless access to trials and reduces administrative burden, while the Re:Cognition Health Academyinvests in the professional development of our teams, fostering excellence in patient care.
This nomination recognises not only our scientific leadership and innovation but also our holistic approach to patient care, research, education and public engagement. Through our Brain & Mind Foundation, collaborations with digital-first home care providers like Cera, and expansion of diagnostic and treatment pathways, Re:Cognition Health continues to shape the future of neurological care.
Being shortlisted for the HealthInvestor Award is a testament to the dedication of our teams and the impact of our patient-centred approach. We remain committed to transforming the landscape of brain and mind health, delivering early diagnosis, cutting-edge therapies and hope to patients and families worldwide.
